Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.40 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146402 | 1.00 | KMT2A (0.45) | KMT2AL3MBTL1KCNA3NPFFR1NPFFR2 | |
| SCHEMBL459129 | 1.00 | KMT2A (0.45) | KMT2AL3MBTL1KCNA3NPFFR1NPFFR2 | |
| SCHEMBL146363 | 0.88 | KMT2A (0.48) | KMT2AL3MBTL1KCNA3NPFFR1NPFFR2 | |
| SCHEMBL1721452 | 0.88 | KMT2A (0.48) | KMT2AL3MBTL1KCNA3NPFFR1NPFFR2 | |
| SCHEMBL146364 | 0.88 | KMT2A (0.48) | KMT2AL3MBTL1KCNA3NPFFR1NPFFR2 | |
| SCHEMBL1721155 | 0.87 | SIGMAR1 (0.43) | KMT2AL3MBTL1MAOBMAOADRD2 | |
| SCHEMBL1721160 | 0.87 | SIGMAR1 (0.43) | KMT2AL3MBTL1MAOBMAOADRD2 | |
| SCHEMBL3931356 | 0.82 | SIGMAR1 (0.41) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL3931359 | 0.82 | SIGMAR1 (0.41) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL7496942 | 0.81 | KMT2A (0.52) | KMT2AL3MBTL1KCNA3NPFFR1NPFFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | KMT2A 3204/4885L3MBTL1 4277/4885KCNA3 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.